Related references
Note: Only part of the references are listed.Maturation and function of human dendritic cells are regulated by B lymphocytes
Ahsen Morva et al.
BLOOD (2012)
CD40-Activated B Cells Can Efficiently Prime Antigen-Specific Naive CD8+ T Cells to Generate Effector but Not Memory T cells
Melissa Mathieu et al.
PLOS ONE (2012)
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells
Yohei Iwata et al.
BLOOD (2011)
Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand
Ashish Jain et al.
BLOOD (2011)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
Activated T cells induce rapid CD83 expression on B cells by engagement of CD40
Birte Kretschmer et al.
IMMUNOLOGY LETTERS (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
CD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma
Karin U. Sorenmo et al.
PLOS ONE (2011)
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis
Tiziana Schioppa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Adjuvant Effects of Antibodies
Mark J. Smyth et al.
SCIENCE (2011)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy
Chao Wu et al.
VIROLOGY JOURNAL (2010)
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential
E. Kondo et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Selective Targeting of B Cells with Agonistic Anti-CD40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL/lpr Mice
Paul A. Blair et al.
JOURNAL OF IMMUNOLOGY (2009)
Using CD40-activated B Cells to Efficiently Identify Epitopes of Tumor Antigens
Eisei Kondo et al.
JOURNAL OF IMMUNOTHERAPY (2009)
CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides
Tahamtan Ahmadi et al.
IMMUNOLOGY (2008)
The 'short' history of regulatory B cells
Claudia Mauri et al.
TRENDS IN IMMUNOLOGY (2008)
A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response
Isabelle Miconnet et al.
VACCINE (2008)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospect of targeting the CD40 pathway for cancer therapy
Robert H. Vonderheide
CLINICAL CANCER RESEARCH (2007)
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants
M von Bergwelt-Baildon et al.
BLOOD (2006)
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines
GW Stone et al.
JOURNAL OF VIROLOGY (2006)
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo
BA Hanks et al.
NATURE MEDICINE (2005)
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
CM Coughlin et al.
BLOOD (2004)
SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane
RM Siegel et al.
JOURNAL OF CELL BIOLOGY (2004)
Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation
PA Stumbles et al.
JOURNAL OF IMMUNOLOGY (2004)
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex
N Holler et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
MS von Bergwelt-Baildon et al.
BLOOD (2002)
CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity
GJD van Mierlo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: Evidence of a reversible acid-denatured molten globule
JE Matsuura et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2001)
Phase I study of recombinant human CD40 ligand in cancer patients
RH Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
